While 2017 was a busy year for biosimilar approvals by the FDA, Rick Lozano, vice president of biosimilars and integrated business development at AmerisourceBergen, feels that the biggest developments in biosimilars were those being made outside the regulatory or clinical spheres. In an interview with The Center for Biosimilars®, Lozano said that “There are distractions and defense strategies in the market that continue to be slowing the pace” of bringing biosimilars to the market.
While 2017 was a busy year for biosimilar approvals by the FDA, Rick Lozano, vice president of biosimilars and integrated business development at AmerisourceBergen, feels that the biggest developments in biosimilars were those being made outside the regulatory or clinical spheres. In an interview with The Center for Biosimilars®, Lozano said that “There are distractions and defense strategies in the market that continue to be slowing the pace” of bringing biosimilars to the market.
Lozano reported that, in his work at AmerisourceBergen, he does not see biosimilars as fitting under a typical brand-name drug platform or under a generic drug platform; instead, he is focused on developing a unique approach to these products to help them thrive in the marketplace. Among Lozano’s initiatives is helping biosimilar developers to overcome market delays through commercialization strategies, especially with respect to aligned patient services and hub services that are either similar to or “above and beyond” what the innovator offers.
“The challenge of patient service, when we saw the first few entrances into the market, is making sure you have copay assistance in place, making sure the flow of patient services goes through the provider, and having the correct hub to support that in the background," he said.
Pure-play biosimilar developers, said Lozano, may not be deeply familiar with the patient programs that the reference product sponsor has in place, and may need help with research that will allow them to implement programs, educate patients, and provide nursing support.
Patients aren’t the only stakeholders who are seeking support. According to Lozano, providers are increasingly looking to industry to provide education about biosimilar therapies. Given how critical it is to build providers’ confidence in biosimilars, “We take it upon ourselves to work with manufactures to get the support services to educate providers so they can educate their patients,” said Lozano. Through its ION Solutions program, AmerisourceBergen conducts outreach to community oncologists not only to educate them on the safety and efficacy of biosimilars, but also to reassure them that payers have the right plans in place to support biosimilars, and that these therapies will remain in the market for the long term.
Looking ahead to 2018, Lozano hopes to see alignment across stakeholder groups—from policy makers and payers to manufacturers and wholesalers—in making the marketplace for biosimilars sustainable.
“2018 needs to be a year where stakeholders align to where there’s access to these products,” said Lozano, “and policies allow [biosimilars] to be on commercial plans—allow them to have a competitive market.”
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.